Lincomycin
| Clinical data | |
|---|---|
| Trade names | Biocine, Lincocin | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a609005 | 
| Routes of administration | IM/IV | 
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | N/A | 
| Elimination half-life | 5.4 ± 1.0 h after IM or IV administration | 
| Excretion | Kidney and bile duct | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.005.296 | 
| Chemical and physical data | |
| Formula | C18H34N2O6S | 
| Molar mass | 406.54 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (what is this?) (verify) | |
Lincomycin is a lincosamide antibiotic that comes from the actinomycete Streptomyces lincolnensis. A related compound, clindamycin, is derived from lincomycin by using thionyl chloride to replace the 7-hydroxy group with a chlorine atom with inversion of chirality. It was released for medical use in September 1964.